- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Small cell lung cancer
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Atezolizumab – July 2019
Atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq®
Last updated
15 November 2019